Correlation Between Cidara Therapeutics and Enveric Biosciences

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Cidara Therapeutics and Enveric Biosciences at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cidara Therapeutics and Enveric Biosciences into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Cidara Therapeutics and Enveric Biosciences, you can compare the effects of market volatilities on Cidara Therapeutics and Enveric Biosciences and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cidara Therapeutics with a short position of Enveric Biosciences. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cidara Therapeutics and Enveric Biosciences.

Diversification Opportunities for Cidara Therapeutics and Enveric Biosciences

0.06
  Correlation Coefficient

Significant diversification

The 3 months correlation between Cidara and Enveric is 0.06. Overlapping area represents the amount of risk that can be diversified away by holding Cidara Therapeutics and Enveric Biosciences in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Enveric Biosciences and Cidara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cidara Therapeutics are associated (or correlated) with Enveric Biosciences. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Enveric Biosciences has no effect on the direction of Cidara Therapeutics i.e., Cidara Therapeutics and Enveric Biosciences go up and down completely randomly.

Pair Corralation between Cidara Therapeutics and Enveric Biosciences

Given the investment horizon of 90 days Cidara Therapeutics is expected to generate 0.49 times more return on investment than Enveric Biosciences. However, Cidara Therapeutics is 2.04 times less risky than Enveric Biosciences. It trades about -0.13 of its potential returns per unit of risk. Enveric Biosciences is currently generating about -0.54 per unit of risk. If you would invest  2,488  in Cidara Therapeutics on November 9, 2024 and sell it today you would lose (365.00) from holding Cidara Therapeutics or give up 14.67% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Cidara Therapeutics  vs.  Enveric Biosciences

 Performance 
       Timeline  
Cidara Therapeutics 

Risk-Adjusted Performance

Good

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
Enveric Biosciences 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Enveric Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in March 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Cidara Therapeutics and Enveric Biosciences Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Cidara Therapeutics and Enveric Biosciences

The main advantage of trading using opposite Cidara Therapeutics and Enveric Biosciences positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cidara Therapeutics position performs unexpectedly, Enveric Biosciences can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Enveric Biosciences will offset losses from the drop in Enveric Biosciences' long position.
The idea behind Cidara Therapeutics and Enveric Biosciences pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.

Other Complementary Tools

Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets